Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

41.22 1.12 +2.79%
Market cap
$6.7B
P/E
102×
Fwd P/E
−108×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
3.85% 9.36% 14.72% 22.40%

+8 more TTM periods

Piotroski F-Score
3 4 7 8
ROA
1.99% 4.82% 10.64% 15.11%
ROIC
2.76% 4.36% 31.75% 36.01%
Return on Tangible Assets
6.13% 15.59% 15.03% 22.38%
Average Days of Receivables
99.91 95.23 82.61 85.03
Free Cash Flow per Share
1.33 1.33 2.92 2.97
Free Cash Flow
222.71 221.18 481.42 490.91
Capital Expenditures
(28.47) (35.02) (39.33) (50.17)
Other line items
Cash ROIC
5.61% 5.86% 15.34% 17.26%
Accounts Receivable Turnover
4.11 4.30 4.11 4.22
Accounts Payable Turnover
0.89 0.87 0.83 1.13
Inventory Turnover
1.05 0.80 1.04 1.11
Average Days of Payables
471.29 511.36 537.99 369.50
Days of Inventory on Hand
423.78 588.48 365.31 328.28
Tax Rate
(0.32) (0.25) (0.17) (0.16)
Research and Development Expense of Revenue
23.45% 22.75% 21.95% 19.00%
Selling, General and Administrative Expense of Revenue
50.44% 50.85% 47.53% 43.47%
Share Based Compensation of Revenue
7.10% 7.18% 6.69% 6.13%
Interest Coverage
2.04 5.12 — —
Operating CF/Net income
3.80 1.68 2.15 1.60
Depreciation/Fixed assets
0.48 0.24 0.12 0.12
Capex/Depreciation
(0.27) (0.67) (1.45) (1.66)
Revenue per Share
9.98 9.40 8.96 9.22
Operating CF per Share
1.50 1.54 3.16 3.28
Capex per Share
(0.17) (0.21) (0.24) (0.30)
Capex to Sales
0.02 0.02 0.03 0.03

Fold the line items

Columns are period end dates